AKT1 and asthma: Our molecular docking results demonstrated that the three core active components of BYD can directly target the three core targets of asthma, implying that quercetin, kaempferol, and luteolin in BYD may exert therapeutic effects by intervening and modulating the PI3K/AKT signaling pathway related to asthma.